-5%
Tripar (Trihexyphenidyl) is a centrally acting anticholinergic that blocks muscarinic receptors, with preference for the M1 subtype in the brain. It reduces cholinergic activity and may indirectly increase dopamine release in the striatum, improving motor symptoms in Parkinson’s disease.Â
Not recommended due to lack of established safety and efficacy data.
Tripar is used as an adjunctive therapy in managing all types of Parkinsonism, including idiopathic, arteriosclerotic, and postencephalitic. It is particularly effective when used alongside levodopa. Additionally, it is indicated to relieve extrapyramidal side effects caused by central nervous system medications such as phenothiazines, thioxanthenes, butyrophenones, and dibenzoxazepines.